Semaglutide
Semaglutide is a GLP-1 receptor agonist used to treat type 2 diabetes by mimicking the gut hormone GLP-1 to lower blood sugar, promote insulin secretion, reduce appetite, and support long-term weight management.
Brief glance
The primary outcome is Weight Loss, but it's also used for Metabolic. This compound is considered a Peptide. It is not currently indicated as compoundable in 503A pharmacies. It is not listed under a DEA schedule.
| Phase | Days | Dosage | Frequency |
|---|---|---|---|
| titration | 1 – 28 | 0.25 mg | Every 7 days |
| titration | 29 – 56 | 0.5 mg | Every 7 days |
| maintenance | 57+ | 1 mg | Every 7 days |
Estimation based on publicly available research; not derived from official prescribing guidance. Not medical advice — consult a qualified healthcare professional before beginning any dosing protocol.
Overview
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes by improving blood sugar control alongside diet and exercise. It is also approved for chronic weight management in adults and children with obesity or overweight with weight-related conditions, and to reduce risks of major cardiovascular events, kidney disease progression, and death in select patients. Common brand names include Ozempic, Wegovy, and Rybelsus, available as weekly injections or daily oral tablets.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used primarily to treat type 2 diabetes by lowering blood glucose levels through increased insulin secretion, reduced glucagon production, and slowed gastric emptying, while also promoting weight loss by suppressing appetite. It shares 94% structural homology with human GLP-1, featuring modifications such as substitutions at key amino acid positions and a fatty acid chain that enhance albumin binding and resistance to enzymatic degradation by dipeptidyl peptidase-4, resulting in a prolonged half-life. Developed by Novo Nordisk, it is available as subcutaneous injections (e.g., Ozempic, Wegovy) approved by the FDA in 2017 and an oral tablet (Rybelsus) approved in 2019, with additional indications for reducing cardiovascular risks and protecting kidney function in certain patients. These mechanisms also contribute to cardiovascular benefits, such as reduced atherosclerosis progression, alongside its role in long-term obesity management.
Benefits
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, improves glycemic control in type 2 diabetes mellitus by reducing HbA1c levels, fasting and postprandial glucose, and body weight through increased insulin secretion, decreased glucagon, and appetite suppression.1,2 It is indicated for chronic weight management in obesity and reduces cardiovascular risk, with clinical trials showing a 20% lower risk of major adverse cardiac events including heart attacks, strokes, and cardiovascular death.1,3 Additional benefits include anti-inflammatory effects that lower cytokines like TNF-α and IL-6, potentially improving endothelial function and cardiac outcomes, as well as renoprotective effects demonstrated by slowed kidney disease progression in type 2 diabetes patients.3,4 It also modestly lowers systolic and diastolic blood pressure.1,3
Side effects
Semaglutide commonly causes gastrointestinal side effects such as nausea (16-44% of users), vomiting (5-24%), diarrhea (8-30%), constipation (5-25%), abdominal pain (6-20%), heartburn, and bloating, along with headache, dizziness, fatigue, and injection site reactions, which often improve over time but increase with higher doses.5,6,7 Serious side effects include pancreatitis (severe abdominal pain radiating to the back), acute kidney injury (from dehydration due to GI issues, with reduced urination or swelling), gallbladder problems, allergic reactions (rash, swelling, breathing difficulty), vision changes, increased heart rate, hypoglycemia, and potential thyroid tumors including cancer based on animal studies and warnings.5,6,7,8,9,10 Key safety considerations involve starting at low doses to minimize risks, staying hydrated, monitoring for severe symptoms requiring immediate medical attention like persistent upper abdominal pain or jaundice, and regular check-ups for long-term issues like renal dysfunction or retinopathy, especially in those with comorbidities.5,6,7,11 Gastrointestinal complaints account for about 70% of emergency visits, though serious events are uncommon (fewer than 4 per 1,000 patients).8 Patients should report unusual problems to their doctor promptly.6
Mechanisms of action
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist with 94% structural homology to human GLP-1, mimicking the natural hormone's actions by binding to and activating GLP-1 receptors in the pancreas, gastrointestinal tract, and brain.12,13 It stimulates glucose-dependent insulin secretion from pancreatic β-cells via cAMP/PKA signaling pathways, while suppressing glucagon release from α-cells to reduce hepatic glucose production.12,13,14 Additionally, it slows gastric emptying to delay nutrient absorption and acts on the hypothalamus to decrease appetite and promote satiety, aiding blood glucose control and weight loss.12,13 Structural modifications protect semaglutide from rapid degradation by DPP-4 enzyme and extend its half-life through albumin binding and delayed renal clearance.1,12,13